Sumitomo Mitsui Trust Group Inc. Makes New $728,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,637 shares of the medical equipment provider’s stock, valued at approximately $728,000.

Several other large investors have also modified their holdings of LNTH. Russell Investments Group Ltd. lifted its stake in Lantheus by 10.4% during the first quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider’s stock valued at $2,347,000 after buying an additional 3,560 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Lantheus by 8.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 21,088 shares of the medical equipment provider’s stock valued at $1,313,000 after acquiring an additional 1,670 shares in the last quarter. Vanguard Group Inc. boosted its stake in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after purchasing an additional 389,828 shares during the period. CANADA LIFE ASSURANCE Co grew its position in Lantheus by 30.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 50,078 shares of the medical equipment provider’s stock worth $3,116,000 after purchasing an additional 11,696 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Lantheus during the 1st quarter valued at $1,432,000. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

LNTH has been the subject of several recent analyst reports. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. JMP Securities decreased their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Finally, B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Stock Performance

NASDAQ:LNTH opened at $79.43 on Wednesday. The company has a market capitalization of $5.52 billion, a P/E ratio of 13.22 and a beta of 0.51. The stock’s 50 day moving average price is $104.07 and its 200 day moving average price is $96.66. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.